Cargando…
Is There a Difference in Clinical Features, Microbiological Epidemiology and Effective Empiric Antimicrobial Therapy Comparing Healthcare-Associated and Community-Acquired Vertebral Osteomyelitis?
Background: Empiric antibiotic therapy for suspected vertebral osteomyelitis (VO) should be initiated immediately in severely ill patients, and might be necessary for culture-negative VO. The current study aimed to identify differences between community-acquired (CA) and healthcare-associated (HA) V...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615006/ https://www.ncbi.nlm.nih.gov/pubmed/34827348 http://dx.doi.org/10.3390/antibiotics10111410 |
_version_ | 1784603999944572928 |
---|---|
author | Lang, Siegmund Frömming, Astrid Walter, Nike Freigang, Viola Neumann, Carsten Loibl, Markus Ehrenschwender, Martin Alt, Volker Rupp, Markus |
author_facet | Lang, Siegmund Frömming, Astrid Walter, Nike Freigang, Viola Neumann, Carsten Loibl, Markus Ehrenschwender, Martin Alt, Volker Rupp, Markus |
author_sort | Lang, Siegmund |
collection | PubMed |
description | Background: Empiric antibiotic therapy for suspected vertebral osteomyelitis (VO) should be initiated immediately in severely ill patients, and might be necessary for culture-negative VO. The current study aimed to identify differences between community-acquired (CA) and healthcare-associated (HA) VO in terms of clinical presentation, causative pathogens, and antibiotic susceptibility. Methods: Cases of adult patients with VO treated at a German university orthopaedic trauma center between 2000 and 2020 were retrospectively reviewed. Patient history was used to distinguish between CA and HA VO. Susceptibility of antibiotic regimens was assessed based on antibiograms of the isolated pathogens. Results: A total of 155 patients (with a male to female ratio of 1.3; and a mean age of 66.1 ± 12.4 years) with VO were identified. In 74 (47.7%) patients, infections were deemed healthcare-associated. The most frequently identified pathogens were Staphylococcus aureus (HAVO: 51.2%; CAVO: 46.8%), and Coagulase-negative Staphylococci (CoNS, HAVO: 31.7%; CAVO: 21.3%). Antibiograms of 45 patients (HAVO: n = 22; CAVO: n = 23) were evaluated. Significantly more methicillin-resistant isolates, mainly CoNS, were found in the HAVO cohort (27.3%). The highest rate of resistance was found for cefazolin (HAVO: 45.5%; CAVO: 26.1%). Significantly higher rates of resistances were seen in the HAVO cohort for mono-therapies with meropenem (36.4%), piperacillin–tazobactam (31.8%), ceftriaxone (27.3%), and co-amoxiclav (31.8%). The broadest antimicrobial coverage was achieved with either a combination of piperacillin–tazobactam + vancomycin (CAVO: 100.0%; HAVO: 90.9%) or meropenem + vancomycin (CAVO: 100.0%; HAVO: 95.5%). Conclusion: Healthcare association is common in VO. The susceptibility pattern of underlying pathogens differs from CAVO. When choosing an empiric antibiotic, combination therapy must be considered. |
format | Online Article Text |
id | pubmed-8615006 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86150062021-11-26 Is There a Difference in Clinical Features, Microbiological Epidemiology and Effective Empiric Antimicrobial Therapy Comparing Healthcare-Associated and Community-Acquired Vertebral Osteomyelitis? Lang, Siegmund Frömming, Astrid Walter, Nike Freigang, Viola Neumann, Carsten Loibl, Markus Ehrenschwender, Martin Alt, Volker Rupp, Markus Antibiotics (Basel) Article Background: Empiric antibiotic therapy for suspected vertebral osteomyelitis (VO) should be initiated immediately in severely ill patients, and might be necessary for culture-negative VO. The current study aimed to identify differences between community-acquired (CA) and healthcare-associated (HA) VO in terms of clinical presentation, causative pathogens, and antibiotic susceptibility. Methods: Cases of adult patients with VO treated at a German university orthopaedic trauma center between 2000 and 2020 were retrospectively reviewed. Patient history was used to distinguish between CA and HA VO. Susceptibility of antibiotic regimens was assessed based on antibiograms of the isolated pathogens. Results: A total of 155 patients (with a male to female ratio of 1.3; and a mean age of 66.1 ± 12.4 years) with VO were identified. In 74 (47.7%) patients, infections were deemed healthcare-associated. The most frequently identified pathogens were Staphylococcus aureus (HAVO: 51.2%; CAVO: 46.8%), and Coagulase-negative Staphylococci (CoNS, HAVO: 31.7%; CAVO: 21.3%). Antibiograms of 45 patients (HAVO: n = 22; CAVO: n = 23) were evaluated. Significantly more methicillin-resistant isolates, mainly CoNS, were found in the HAVO cohort (27.3%). The highest rate of resistance was found for cefazolin (HAVO: 45.5%; CAVO: 26.1%). Significantly higher rates of resistances were seen in the HAVO cohort for mono-therapies with meropenem (36.4%), piperacillin–tazobactam (31.8%), ceftriaxone (27.3%), and co-amoxiclav (31.8%). The broadest antimicrobial coverage was achieved with either a combination of piperacillin–tazobactam + vancomycin (CAVO: 100.0%; HAVO: 90.9%) or meropenem + vancomycin (CAVO: 100.0%; HAVO: 95.5%). Conclusion: Healthcare association is common in VO. The susceptibility pattern of underlying pathogens differs from CAVO. When choosing an empiric antibiotic, combination therapy must be considered. MDPI 2021-11-18 /pmc/articles/PMC8615006/ /pubmed/34827348 http://dx.doi.org/10.3390/antibiotics10111410 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lang, Siegmund Frömming, Astrid Walter, Nike Freigang, Viola Neumann, Carsten Loibl, Markus Ehrenschwender, Martin Alt, Volker Rupp, Markus Is There a Difference in Clinical Features, Microbiological Epidemiology and Effective Empiric Antimicrobial Therapy Comparing Healthcare-Associated and Community-Acquired Vertebral Osteomyelitis? |
title | Is There a Difference in Clinical Features, Microbiological Epidemiology and Effective Empiric Antimicrobial Therapy Comparing Healthcare-Associated and Community-Acquired Vertebral Osteomyelitis? |
title_full | Is There a Difference in Clinical Features, Microbiological Epidemiology and Effective Empiric Antimicrobial Therapy Comparing Healthcare-Associated and Community-Acquired Vertebral Osteomyelitis? |
title_fullStr | Is There a Difference in Clinical Features, Microbiological Epidemiology and Effective Empiric Antimicrobial Therapy Comparing Healthcare-Associated and Community-Acquired Vertebral Osteomyelitis? |
title_full_unstemmed | Is There a Difference in Clinical Features, Microbiological Epidemiology and Effective Empiric Antimicrobial Therapy Comparing Healthcare-Associated and Community-Acquired Vertebral Osteomyelitis? |
title_short | Is There a Difference in Clinical Features, Microbiological Epidemiology and Effective Empiric Antimicrobial Therapy Comparing Healthcare-Associated and Community-Acquired Vertebral Osteomyelitis? |
title_sort | is there a difference in clinical features, microbiological epidemiology and effective empiric antimicrobial therapy comparing healthcare-associated and community-acquired vertebral osteomyelitis? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615006/ https://www.ncbi.nlm.nih.gov/pubmed/34827348 http://dx.doi.org/10.3390/antibiotics10111410 |
work_keys_str_mv | AT langsiegmund isthereadifferenceinclinicalfeaturesmicrobiologicalepidemiologyandeffectiveempiricantimicrobialtherapycomparinghealthcareassociatedandcommunityacquiredvertebralosteomyelitis AT frommingastrid isthereadifferenceinclinicalfeaturesmicrobiologicalepidemiologyandeffectiveempiricantimicrobialtherapycomparinghealthcareassociatedandcommunityacquiredvertebralosteomyelitis AT walternike isthereadifferenceinclinicalfeaturesmicrobiologicalepidemiologyandeffectiveempiricantimicrobialtherapycomparinghealthcareassociatedandcommunityacquiredvertebralosteomyelitis AT freigangviola isthereadifferenceinclinicalfeaturesmicrobiologicalepidemiologyandeffectiveempiricantimicrobialtherapycomparinghealthcareassociatedandcommunityacquiredvertebralosteomyelitis AT neumanncarsten isthereadifferenceinclinicalfeaturesmicrobiologicalepidemiologyandeffectiveempiricantimicrobialtherapycomparinghealthcareassociatedandcommunityacquiredvertebralosteomyelitis AT loiblmarkus isthereadifferenceinclinicalfeaturesmicrobiologicalepidemiologyandeffectiveempiricantimicrobialtherapycomparinghealthcareassociatedandcommunityacquiredvertebralosteomyelitis AT ehrenschwendermartin isthereadifferenceinclinicalfeaturesmicrobiologicalepidemiologyandeffectiveempiricantimicrobialtherapycomparinghealthcareassociatedandcommunityacquiredvertebralosteomyelitis AT altvolker isthereadifferenceinclinicalfeaturesmicrobiologicalepidemiologyandeffectiveempiricantimicrobialtherapycomparinghealthcareassociatedandcommunityacquiredvertebralosteomyelitis AT ruppmarkus isthereadifferenceinclinicalfeaturesmicrobiologicalepidemiologyandeffectiveempiricantimicrobialtherapycomparinghealthcareassociatedandcommunityacquiredvertebralosteomyelitis |